Related Experiment Video
Updated: May 23, 2026
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
PKCη is a novel prognostic marker in non-small cell lung cancer
Ella Krasnitsky1, Yael Baumfeld, Janna Freedman
1The Shraga Segal Department of Microbiology and Immunology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
Background:
Novel biomarkers which may serve as therapeutic targets are essential for lung cancer treatment. Here we investigated the prognostic significance of protein kinase Cη (PKCη), a cell cycle regulator involved in tumorigenesis and chemotherapy resistance, in patients diagnosed with non-small cell lung cancer (NSCLC).
Patients And Methods:
Sixty-three chemotherapy-naïve patients were examined for PKCη by immunohistochemistry and divided into PKCη H-Score tertiles (low, intermediate and high). Time until event (relapse or mortality) within one year was determined using Cochran-Armitage test and Cox proportional hazards regression model.
Results:
The distribution of patients according to clinical stage 1-4 was: 27%, 5%, 26% and 42%, respectively. PKCη overexpression was associated with advanced stage (p=0.03) and the risk for an event (p=0.045). Patients of the lowest tertile were less likely to experience an event.
Conclusion:
PKCη is a novel prognostic marker in NSCLC that may predict poor prognosis. The use of PKCη-specific inhibitors in NSCLC may prove valuable.